🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

Recruitingn/aAges 18 Years - 70 YearsAllUniversity of Rome Tor Vergata
NCT06130046 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Kidney transplant recipient at our Institution * Liver transplant recipient at our Institution Exclusion Criteria: * Re-transplantation * Dual kidney transplantation * Combined transplant (kidney-liver, kidney-pancreas) * Autoimmune disease as indication to transplant
💊

What it tests

  • MR-proADM dosage
📍

Where

1 site
University of Rome Tor Vergata
Rome, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy